Trial
NCT05036317
Empagliflozin for the Treatment of Postprandial Hypoglycemia
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
University Hospital, Basel, Switzerland
Collaborators
Boehringer Ingelheim
Condition
Postprandial Hypoglycemia
Intervention
Empagliflozin (Jardiance®
Why stopped
Early terminated after prespecified interim analysis due to lack of efficacy. No relevant safety signals.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-16